Position in OGN
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$7,511,992
+$7,054,681 QoQ
Shares Held
554,800
+1074.4% QoQ
Ownership
0.211%
of shares outstanding
% of Portfolio
0.33%
of 13F equity value
Holder Rank
#60
of 626 holders
Holding Since
Sep 2023
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in OGN Over Time
Shares Held
Position Value (USD)
Derivatives in OGN
reported options exposure · as of Jun 30, 2026CallValue
$276,216
CallShares
20,400
PutValue
$3,385,000
PutShares
250,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Centiva Capital, LP holds $53,156,493 across 8 Drug Manufacturers - General names. OGN ranks #4 (14.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PFE |
Pfizer Inc
|
899,074 | $21,649,701 | |
| 2 | AMGN |
Amgen Inc
|
26,442 | $9,575,177 | |
| 3 | LLY |
ELI LILLY & Co
|
7,922 | $9,501,885 | |
| 4 | OGN |
Organon & Co.
This page
|
554,800 | $7,511,992 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
48,515 | $2,795,434 | |
| 6 | NVO |
Novo Nordisk A S
|
22,000 | $1,054,680 | |
| 7 | MRK |
Merck & Co., Inc.
|
5,405 | $694,542 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
2,953 | $373,082 |
All Filings in OGN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,385,000 | 250,000 | Put | Sole | 2026-08-13 | |
| 2026-06-30 | $276,216 | 20,400 | Call | Sole | 2026-08-13 | |
| 2026-06-30 | $7,511,992 | 554,800 | Shares | Sole | 2026-08-13 | |
| 2025-06-30 | $457,311 | 47,243 | Shares | Sole | 2025-08-13 | |
| 2024-09-30 | $542,756 | 28,372 | Shares | Sole | 2024-11-14 | |
| 2023-09-30 | $550,936 | 31,736 | Shares | Sole | 2023-11-14 | |
| No filing history on record for this holder in this stock. | ||||||